Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor in the clinical development for the treatment and prevention of thromboembolic diseases. Clinical data indicate that dabigatran etexilate has immediate onset of effect, no need for monitoring, predictable and consistent pharmacokinetics and pharmacodynamics-all features that differentiate it from oral vitamin K antagonists (VKAs). Completed phase III studies demonstrated a comparable efficacy and safety profile to enoxaparin in the prevention of venous thromboembolism (VTE) after orthopedic surgery. Ongoing phase III trials are now evaluating the long-term use of dabigatran etexilate for the treatment and secondary prevention of VTE and for prevention of stroke in patients with atrial fibrillation, as a replacement for VKAs. With an immediate, reliable, and predictable anticoagulant effect without the need for coagulation monitoring and the lack of long-term safety concerns, dabigatran etexilate may be a prospective candidate that offers additional benefit over VKAs and parenteral anticoagulants in these settings.
Introduction
Anticoagulant treatment in patients with atrial fibrillation (AF) or venous thromboembolism (VTE) has for decades relied almost exclusively on vitamin K antagonists (VKA), the most widely used of these being warfarin. Unfractionated or low-molecularweight heparin is only given for brief periods as bridging anticoagulation, except in patients with VTE and cancer or in pregnant women. Treatment with VKA is deliberately avoided in a substantial proportion of patients with AF 1 or shortened to a minimum in patients with VTE. Although the proportion of patients with AF eligible for VKA and who actually receive treatment with it has increased slowly during the past decade, even patients with this arrhythmia and prior stroke do not receive VKA. 2 The reasons for this behavior include the need for frequent laboratory monitoring and dose adjustments, the large number of drug interactions, and the fear of bleeding.
The quest for more predictable oral anticoagulants has been pursued for several decades, and the goal was reached, albeit transiently, with the oral direct thrombin inhibitor (DTI) ximelagatran. This drug was launched in June 2004 for the indication of VTE prophylaxis after hip or knee arthroplasty but was subsequently withdrawn from the market and from all ongoing studies in February 2006 due to the risk of liver toxicity. 3 At that point, at least half a dozen other selective and orally administered anticoagulant agents were under clinical development ( Table 1) . Two of these drugs have since the spring of 2008 been approved for VTE prophylaxis after hip or knee arthroplasty in Europe and several countries elsewhere in the world-the reversible oral DTI dabigatran etexilate and the direct factor Xa (FXa) inhibitor, rivaroxaban.
Here, we review the progress in the development of dabigatran etexilate in 2 major indications that remain in clinical phase III studies, stroke prevention in AF (SPAF) and treatment of established VTE.
Characteristics of Dabigatran Etexilate
Dabigatran etexilate is a new, oral, reversible DTI that prevents thrombus formation by specifically and selectively binding to thrombin, a central and essential enzyme involved in the conversion of fibrinogen to fibrin during the coagulation cascade, thereby blocking its activity. Because dabigatran also acts on clot-bound thrombin, it has the potential for treatment of acute venous thrombi. Favorable pharmacokinetic and pharmacodynamic characteristics, including rapid onset and offset of action, a predictable and consistent anticoagulation effect without the need for routine coagulation monitoring, and low potential for drug or food interactions, together with the lack of significant hepatotoxicity and a bleeding risk comparable to other conventional anticoagulants, support its further clinical development. 4 Currently, dabigatran etexilate is being investigated in 5 major therapeutic areas in trials involving more than 46 000 patients. In the setting of primary prevention of VTE, trials have been completed in the European Union (EU), Canada, and other countries and are ongoing in the United States. Phase III studies demonstrated the efficacy and safety of dabigatran etexilate for the prevention of VTE after orthopedic surgery and were pivotal for regulatory approval for this indication in Europe and Canada. Additional areas of therapeutic investigation include treatment of acute VTE, secondary prevention of VTE, SPAF, and prevention of cardiac events in patients with acute coronary syndrome (ACS) and are the focus of this review.
Stroke Prevention in AF
Atrial fibrillation is the most common clinically significant cardiac arrhythmia, affecting an estimated 4.5 million and 2.3 million individuals in the EU and the United States, respectively. 5, 6 The prevalence of AF increases with age, occurring in less than 1% of the general population at <60 years of age but in almost 10% of those >80 years. 7 Patients with AF have a 5-fold greater risk of stroke compared with age-matched controls and a doubling of the risk of death. 8 Moreover, as strokes due to AF tend to be more severe than other types of stroke and are associated with greater disability, 8 there is a substantial burden on health care systems, which is likely to increase, given population demographics. Therefore, SPAF represents a key therapeutic goal. Long-term anticoagulation therapy with VKAs such as warfarin is recommended for individuals with nonvalvular AF who are considered at moderate-tohigh risk of stroke. 6 The most commonly used risk assessment tool is the CHADS 2 index, which assigns scores for recognized risk factors for thromboembolism, including Congestive heart failure or left ventricular dysfunction, Hypertension, >75 years of Age, Diabetes mellitus, or previous ischemic Stroke or transient ischemic attack. Each risk factor counts for 1 point except previous stroke or transient ischemic attack, which counts for 2 points. International guidelines recommend antithrombotic treatment (aspirin or VKA) for those with a CHADS 2 score !1, and VKA for those with a CHADS 2 score !2 because it is likely that the thromboprophylactic effect will outweigh the risk of bleeding in patients at higher risk of stroke. 6 Dose-adjusted VKA therapy reduces the incidence of stroke in patients with nonvalvular AF by about two thirds compared with placebo. 9 With such a potent effect, current guidelines recommend longterm VKA administration (international normalized ratio [INR] target range 2.0-3.0) across a range of risk levels. 10 Despite this benefit, less than half of eligible patients receive appropriate oral VKA anticoagulation. 1, 11, 12 This underuse is due in part to the well-documented limitations of VKAs, including a less than ideal pharmacokinetic profile necessitating individual dose titration and intensive monitoring coupled with frequent dose adjustment. 13 Some of the interindividual dosing variability results from polymorphisms in the genes coding for the enzymes CYP2C9 and VKORC1 responsible for the metabolism of warfarin. 14 Dabigatran etexilate is not metabolized by the microsomal enzymes in the liver but predominantly excreted via the urine, and therefore, the potential for this type of variability is much smaller. Vitamin K antagonists have a very narrow therapeutic window as well as interactions with dietary vitamin K and a number of other medications, resulting in a need for constant patient education, compliance, and frequent follow-up. 13 Although the benefit-risk ratio is positive, the fear of bleeding complications makes many physicians reluctant to prescribe VKAs for eligible patients.
These limitations raise practical issues associated with the use of VKA therapy with implications for patients and health care systems. As a consequence, VKA treatment is often poorly used, leading to ineffective anticoagulation or increased bleeding or underused because of the inconvenience of frequent monitoring. 1 In the setting of controlled clinical trials, poor anticoagulation control (defined as the failure to maintain a target INR of 2.0-3.0) among patients with AF prescribed warfarin for stroke prevention doubled the frequencies of stroke, major bleeding, and death compared with those achieving good control. 15 It appears, therefore, that the management of anticoagulation is far from optimal in these patients with a clear unmet need for alternative oral anticoagulants that are safe and effective with consistent and predictable effects.
Novel Anticoagulant Treatment
Several new treatments are currently undergoing development in an attempt to replace VKA in the setting of SPAF. Of these, agents that directly target single coagulation proteases, including orally active small molecules such as the oral DTIs and FXa inhibitors, show most promise. These agents share a number of characteristics, including a predictable anticoagulant response and a low potential for food or drug-drug interactions, which means that they can be given in fixed doses without the need for coagulation monitoring. This makes them more convenient than VKAs.
Ximelagatran, the first orally available reversible DTI, provided ''proof of principle'' evidence that an oral anticoagulant specifically targeting thrombin and not requiring routine monitoring could be as effective as warfarin in preventing stroke and systemic embolic events in patients with AF, with a bleeding profile similar to or better than warfarin. 16 Unfortunately, prolonged therapy with ximelagatran also resulted in idiosyncratic hepatic toxicity, 17 resulting in its withdrawal from clinical development. Dabigatran etexilate, the next oral reversible DTI, appears to be devoid of these liver problems. Enrolment in a large phase III trial is now completed, with results expected in late 2009. Several oral FXa inhibitors (rivaroxaban, apixaban, DU-176b, and betrixaban), 1 parenteral FXa inhibitor (biotinylated idraparinux), and 1 further DTI (AZD0837) are also being evaluated in ongoing trials for chronic treatment of patients with AF. Dabigatran etexilate is currently the most advanced novel oral anticoagulant in the development of SPAF.
Dabigatran Etexilate: Phase II Trials
The dose-ranging phase II trials, Prevention of Embolic and ThROmbotic events (PETRO), 18 and its long-term extension PETRO-Ex, 19 (Figure 1 ). Although the half-life of dabigatran is approximately 12 to 14 hours, dabigatran etexilate was given bid rather than qd based on the premise that the maintenance of elevated trough levels and low peak-totrough ratios associated with the bid regimen are important for both efficacy (reduction in stroke rate) and safety (reduction in bleeding rate). Patients had a median AF duration of 4 years, and a median of 3 additional risk factors for thromboembolism. The primary end point was the frequency of major and/ or clinically significant bleeding events.
Major bleeding occurred in 4 of 64 (6.2%) patients treated with the combination of 300 mg bid dabigatran etexilate and aspirin (versus 0 of 105 in the 300 mg bid dabigatran etexilate monotherapy group, P < .02, Fisher exact test, 2-tailed). Consequently, aspirin was discontinued in that group and patients were merged with the 300-mg monotherapy group. The rate of bleeding in this group did not differ from rates observed in the other treatment groups ( Table 2 ). There was no statistically significant difference between the 3 dose-groups regarding adverse events leading to premature discontinuation.
In total, 361 (of 432) patients treated with dabigatran etexilate who completed PETRO continued in PETRO-Ex. 19 Patients in the warfarin arm (n ¼ 70) of PETRO discontinued therapy after 12 weeks and did not participate in the extension trial. Therefore, PETRO-Ex was primarily observational and was aimed at assessing longer term rates of thromboembolic events, bleeding events, and liver enzyme elevations. With the exception of the 50-mg bid dose group who were switched to 150 mg qd, all patients were initially maintained on the same dabigatran doses as in PETRO. However, after several months of treatment a higher frequency of major bleeding events in the 300-mg bid group (7.1%) and the risk of stroke in the 150-mg qd group (8.1%) emerged. Consequently, patients in these groups were switched to dabigatran 300 mg qd or 150 mg bid. Together PETRO and PETRO-Ex contributed over 1000 patient years of exposure to various doses of dabigatran etexilate (Table 3 ). These trials defined a maximum tolerated dose and an ineffective dose. Stroke and major bleeding rates were dose related. While the risk of stroke was lowest with dabigatran etexilate 150 or 300 mg bid (1.0 and 1.2 per 100 patient years, respectively), the 300-mg bid regimen was also associated with an increased risk of major bleeding (12.2 per 100 patient years), particularly when combined with aspirin (8.5 vs 3.2 events per 100 patient years). The bleeding risk with 150 mg bid (4.2 events per 100 patient years), however, was similar to that of warfarin. There was no evidence of drug-related liver toxicity in any patient who received dabigatran. All abnormal liver function test results resolved completely either during continued therapy or after treatment discontinuation. Only 3 patients had evidence of severe liver toxicity, defined as elevation in alanine transaminase or aspartate transaminase level >3 times the upper limit of the normal (ULN) reference range and bilirubin levels twice the ULN within 30 days. These events were attributed to cholelithiasis, gall stones, and pancreatic adenocarcinoma. Based on these findings, it was concluded that the dose regimen of 150 mg bid provides optimal efficacy/safety (ie, stroke/bleeding risk) balance for phase III trials. A lower dose of 110 mg bid was also proposed to be tested in phase III, based on interpolation of phase II data, consideration of the time course of anticoagulant effect of dabigatran, and the proven effectiveness of the total daily dose of 220 mg in orthopedic prophylaxis trials. 20, 21 Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) is a prospective, randomized, open-label multinational phase III trial with blinded evaluation of all outcomes (PROBE design). 22 Two blinded doses of dabigatran etexilate (110 mg or 150 mg bid) are being compared with open-label warfarin (targeted INR 2-3) in 18 113 patients with nonvalvular AF and at least 1 other major risk factor for thromboembolism. The median treatment duration is approximately 2 years with a minimum of 1 year follow-up. The primary aim is to show that at least 1 dose of dabigatran is noninferior to warfarin for the prevention of stroke (including hemorrhagic stroke) or systemic embolism (the primary outcomes). In contrast to previous trials in which the vast majority of patients (73%-84%) were on VKAs at the time of trial entry, [23] [24] [25] the protocol allows for balanced representation of warfarin-naive (<2 months of VKA) and warfarin-experienced patients. Because inception cohorts on warfarin may be at a far higher risk of major bleeding than warfarinexperienced patients, 26 it will be important to determine whether a new anticoagulant can alter the benefit-risk ratio in this population. Evaluation of 2 doses of a new agent in a phase III trial is unusual but it might allow for tailoring of the dose to optimize the benefit-risk balance. With the low dose, there is the potential for similar efficacy to adjusted-dose warfarin with less bleeding. The open-label design is closer to real world management of dabigatran than a double-blind trial versus warfarin but requires robust results to be convincing. Recruitment in RE-LY was completed in December 2007, and results are anticipated later this year. Patients in the dabigatran groups who complete the RE-LY trial are being offered the possibility of continuing in the openlabel long-term safety extension trial, RELY-ABLE. More than 6000 patients are expected to be enrolled for up to 28 months of treatment.
Other Therapeutic Areas

Treatment of VTE
Therapy for VTE is aimed at limiting or preventing the extension of the thrombus, as well as recurrence of VTE and (fatal) pulmonary embolism (PE). Current management strategies involve initial treatment with heparins or fondaparinux for at least 5 days followed by long-term oral anticoagulation with VKAs. 27 Previous studies involving the oral DTI ximelagatran showed that the use of fixed dosing without coagulation monitoring was effective for 6 months treatment of deep vein thrombosis (DVT) with or without PE, 28 with a low rate of major bleeding events.
Two phase III trials, RE-COVER I and II (Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism) are comparing dabigatran etexilate 150 mg bid with warfarin (dosed to achieve a target INR of 2-3) preceded by initial treatment (5-10 days) with an approved parenteral anticoagulant for the treatment of acute symptomatic VTE. The duration of study treatment was 6 months (Figure 2 ). 29 The selection of the dose regimen used in these trials was based on results from the dose-ranging Boehringer Ingelheim Study in Thrombosis (BISTRO II) and PETRO trials, 18, 30 the aim being to use a full anticoagulant dose of dabigatran etexilate, while preserving safety, particularly with respect to bleeding events, even when used with concomitant aspirin (as in PETRO). For each one of these double-blind double-dummy trials, the sample size in the combined groups is 2550 patients, which provides an estimated power of over 90% to assess noninferiority to warfarin, based on an event hazard rate of 2% to 5% over the 6-month treatment period. The primary aim is to show that the efficacy of dabigatran is at least noninferior to full-dose warfarin as measured by the prevention of recurrent symptomatic or fatal VTE. Initial VTE as well as any symptomatic recurrence will be confirmed by established objective definitive diagnostic testing and adjudicated by a central independent committee who will be blinded to treatment allocation. RE-COVER I has completed recruitment and follow-up of 2564 patients, and the results are expected to be available in late 2009. RE-COVER II has almost identical protocol design to RE-COVER I, except that many Asian countries are also participating, which will provide additional information on effects of dabigatran in various ethnic populations.
Extended Secondary Prevention of VTE
The treatment with anticoagulants for VTE is essentially ''secondary prevention'' because only thrombolytic agents provide true resolution therapy for an acute thrombus. Traditionally, the duration of secondary prophylaxis after VTE was limited to 3 or 6 months. At least for the first event of thromboembolism, most physicians are hesitant about longer duration of anticoagulation due to the inconvenience and bleeding risks associated with VKAs. Due to the absence of laboratory monitoring requirements with the new anticoagulants, there is an increased interest in extension of secondary prophylaxis beyond the first 6 months.
Studies with ximelagatran provided ''proof-ofconcept'' for the benefit of fixed dosing with oral reversible DTIs in this setting, with a significantly lower cumulative risk of VTE recurrence (2.8%) compared with placebo (12.6%; P < .001) and no significant increase in bleeding complications. 31 Consequently, 2 phase III, long-term trials (RE-MEDY and RE-SONATE) are comparing the efficacy and safety of dabigatran etexilate versus warfarin in patients with recurrent VTE previously treated with warfarin. 32, 33 In RE-MEDY (Secondary Prevention of Venous ThromboEmbolism), patients with symptomatic acute VTE treated with a VKA for 3 to 12 months are randomized to double-blind treatment for 18 to 36 months with either oral dabigatran etexilate 150 mg bid or warfarin (INR 2.0-3.0). The study is powered to demonstrate noninferiority versus warfarin, assuming a 2% hazard rate of recurrent VTEs. Approximately 2400 patients will be recruited. In RE-SONATE, approximately 1800 patients with symptomatic DVT or PE who completed 6 to 18 months of treatment with a VKA will be randomized to double-blind treatment with either oral dabigatran etexilate 150 mg bid or placebo for a further 6 months. In both the trials, the primary efficacy outcomes are symptomatic recurrent DVT or PE during the treatment period and the main safety outcome is bleeding events during treatment.
The choice of a double-blind, double-dummy design for the 4 phase III studies in patients with VTE is challenging for investigators but will result in high-quality data to demonstrate the efficacy of dabigatran etexilate. At the time of planning these studies, the strong preference of the US Food and Drug Administration was to perform double-blind trials, whereas the European Medicines Agency primarily requested the use of an active comparator in both the initial treatment and the extended secondary prophylaxis trials. The dabigatran phase III VTE program with 4 trials should hopefully satisfy all the requirements from the regulatory authorities.
Secondary Prevention of Recurrent Coronary Events After Acute Coronary Syndrome
The ongoing placebo-controlled, dose-finding phase II trial RE-DEEM (RandomizEd Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel) 34 aims to investigate dabigatran etexilate, in combination with aspirin and clopidogrel, for secondary prevention of cardiac events in patients with ACS. A total of 1800 patients will be recruited within 14 days of diagnosis of STsegment elevation or non-ST-segment elevation myocardial infarction and at the cessation of parenteral anticoagulation, and with at least 1 additional high-risk feature (eg, age, diabetes, heart failure). This is a challenging therapeutic area, given the inherent increased risk of bleeding when combining several antithrombotic agents and simultaneously inhibiting both platelet and coagulation activity. Reflecting these concerns, treatment is initiated with a low (even subtherapeutic) dose of dabigatran etexilate, 50 mg bid, with gradual titration to the same doses used in the SPAF program (110 and 150 mg bid). The primary outcome is a composite of major and clinically relevant minor bleeding events over 6 months of treatment, with secondary outcome measures, including coagulation biomarkers and morbidity/mortality composites.
Use of Dabigatran in Patients Undergoing Cardiac Catheterization
Finally, an ongoing study is evaluating the safety and pharmacodynamics of 2 doses of dabigatran etexilate in 50 patients undergoing percutaneous coronary intervention. 35 The primary outcome is anticoagulant efficacy, evaluated on the basis of the number of patients requiring rescue anticoagulant and/or with clinical signs of catheter-related thrombosis during an interventional procedure at 2 weeks. Secondary outcomes include the number of patients experiencing catheter-related thrombotic events and or vessel closure or new thrombus or no reflow, coagulation parameters before and after study drug administration.
Conclusion
Dabigatran etexilate is an oral reversible DTI that is at the forefront of a new generation of oral anticoagulants targeting an unmet clinical need in the prevention and treatment of acute and chronic thromboembolic diseases. Clinical studies have already demonstrated that dabigatran etexilate has comparable safety and efficacy to enoxaparin for VTE prophylaxis in patients undergoing orthopedic surgery. In the setting of stroke prevention in patients with nonvalvular AF, preliminary data from 1 study suggest that dabigatran etexilate may be a reasonable alternative to warfarin, with relatively low rates of bleeding. Results are awaited from the pivotal RE-LY trial in late 2009 to provide definitive information in this setting. Additional trials are evaluating the efficacy and safety of dabigatran etexilate for the treatment of acute VTE, secondary prevention of VTE, and prevention of cardiac events in patients with ACS.
An oral therapy with a reliable and predictable anticoagulant effect without the need for coagulation monitoring or any long-term safety concerns would be a major advance in the management of patients with various thromboembolic disorders. In these respects, dabigatran etexilate is a potential candidate that may offer additional benefit over VKAs and parenteral anticoagulants in these settings.
